SCHEMBL3943250

SCHEMBL3943250

O=[N+]([O-])c1ccccc1OS(=O)(=O)O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.56
TDP1 Q9NUW8 1/20 0.56
NPC1 O15118 2/20 0.55
RAB9A P51151 2/20 0.55
RECQL P46063 1/20 0.55
L3MBTL1 Q9Y468 2/20 0.50
HPGD P15428 1/20 0.50
KMT2A Q03164 6/20 0.48
MEN1 O00255 3/20 0.48
HTT P42858 1/20 0.47
KDM4E B2RXH2 1/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
MMP1 P03956 1/20 0.46
MMP2 P08253 1/20 0.46
MMP9 P14780 1/20 0.46
MMP8 P22894 1/20 0.46
MMP13 P45452 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
MAPT P10636 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3943254 1.00 ALDH1A1 (0.56) ALDH1A1TDP1NPC1RAB9ARECQL
Hydrazine SCHEMBL28200090 0.96 ALDH1A1 (0.53) ALDH1A1TDP1NPC1RAB9ARECQL
SCHEMBL4305407 0.85 ALDH1A1 (0.60) ALDH1A1TDP1NPC1RAB9ARECQL
SCHEMBL2501666 0.81 ALDH1A1 (0.56) ALDH1A1TDP1NPC1RAB9ARECQL
SCHEMBL2333531 0.81 ALDH1A1 (0.56) ALDH1A1TDP1NPC1RAB9ARECQL
SCHEMBL31443947 0.81 ALDH1A1 (0.56) ALDH1A1TDP1NPC1RAB9ARECQL
SCHEMBL4102754 0.81 ALDH1A1 (0.61) ALDH1A1TDP1NPC1RAB9ARECQL
SCHEMBL27494789 0.80 ALDH1A1 (0.59) ALDH1A1TDP1NPC1RAB9ARECQL
SCHEMBL8321794 0.80 CTSB (0.53) ALDH1A1TDP1NPC1RAB9AHPGD
SCHEMBL8321796 0.80 CTSB (0.53) ALDH1A1TDP1NPC1RAB9AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4182452-A1 METHODS FOR SYNTHESIZING NON-ANTICOAGULANT HEPARAN SULFATE Optimvia, LLC (US) 2023-05-24 EP claimed
EP-3997238-A1 METHODS FOR SYNTHESIZING ANTICOAGULANT POLYSACCHARIDES Optimvia, LLC (US) 2022-05-18 EP claimed
EP-3911737-A1 ENGINEERED ARYL SULFATE-DEPENDENT ENZYMES Optimvia, LLC (US) 2021-11-24 EP claimed
WO-2021007429-A1 METHODS FOR SYNTHESIZING ANTICOAGULANT POLYSACCHARIDES OPTIMVIA LLC (US) 2021-01-14 WO claimed
WO-2020150350-A1 ENGINEERED ARYL SULFATE-DEPENDENT ENZYMES OPTIMVIA, LLC (US) 2020-07-23 WO claimed
WO-2018175464-A1 ENZYMATIC PREPARATION OF INCREASED ANTICOAGULANT BOVINE SOURCED HEPARIN RENSSELAER POLYTECHNIC INSTITUTE (US) 2018-09-27 WO claimed
EP-2761017-A1 SYSTEMS AND METHODS FOR PREDICTING RESPONSE TO MINOXIDIL FOR THE TREATMENT OF ANDROGENETIC ALOPECIA Follea International Limited (CN) 2014-08-06 EP claimed
WO-2013049258-A1 SYSTEMS AND METHODS FOR PREDICTING RESPONSE TO MINOXIDIL FOR THE TREATMENT OF ANDROGENETIC ALOPECIA FOLLEA INTERNATIONAL (US) 2013-04-04 WO claimed
WO-2009014715-A2 ENZYMATIC SYNTHESIS OF SULFATED POLYSACCHARIDES WITHOUT IDURONIC ACID RESIDUES THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2009-01-29 WO claimed
EP-1885865-A2 ENZYMATIC SYNTHESIS OF SULFATED POLYSACCHARIDES The University of North Carolina at Chapel Hill (US) 2008-02-13 EP claimed
WO-2006124801-A2 ENZYMATIC SYNTHESIS OF SULFATED POLYSACCHARIDES THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2006-11-23 WO claimed
EP-0531537-A1 HIRUDIN ANALOGUE OR SALT THEREOF, PRODUCTION THEREOF, AND ANTICOAGULANT CONTAINING THE SAME AS ACTIVE INGREDIENT JAPAN ENERGY CORPORATION (JP) 1993-03-17 EP claimed
CN-118078847-A Alopecia preventing composition and preparation method and application thereof 开远市洁白洗涤用品有限公司 2024-05-28 CN disclosed
US-11939303-B2 Sulfamate derivatives of 4-(1-phenyl-1H-[1,2,3]triazol-4-yl)-phenol, derivatives of 4-(1-phenyl-1H-[1,2,3]triazol-4-yl)-phenol, their medical use and the method of obtaining 4-(1-phenyl-1H-[1,2,3]triazol-4-yl)-phenyl sulfamate derivatives POLITECHNIKA GDANSKA (PL) 2024-03-26 US disclosed
US-20240076634-A1 ENGINEERED ARYL SULFATE-DEPENDENT ENZYMES GINKGO BIOWORKS, INC. 2024-03-07 US disclosed
WO-2023239972-A1 MINOXIDIL ADJUVANT THERAPIES Jupiter Wellness, Inc. (US) 2023-12-14 WO disclosed
WO-2000001691-A1 PROCESS FOR MAKING FARNESYL-PROTEIN TRANSFERASE INHIBITORS MERCK & CO., INC. (US) 2000-01-13 WO disclosed
WO-2000001674-A1 PROCESS FOR MAKING 1,5-DISUBSTITUTED IMIDAZOLES MERCK & CO., INC. (US) 2000-01-13 WO disclosed
WO-1998003636-A9 NOVEL ARYLSULFOTRANSFERASE 1998-05-22 WO disclosed
WO-1998003636-A1 NOVEL ARYLSULFOTRANSFERASE BIO-TECHNICAL RESOURCES (US) 1998-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11939303-B2 Sulfamate derivatives of 4-(1-phenyl-1H-[1,2,3]triazol-4-yl)-phenol, derivatives of 4-(1-phenyl-1H-[1,2,3]triazol-4-yl)-phenol, their medical use and the method of obtaining 4-(1-phenyl-1H-[1,2,3]triazol-4-yl)-phenyl sulfamate derivatives SULT1E1, SULT2A1, SULT1A1 ALDH1A1 507/4885TDP1 2518/4885NPC1 3499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.